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Phospholipid-based deformable nanovesicles (DNVs) that have flexibility in shape offer an adaptable and facile method to
encapsulate diverse classes of therapeutics and facilitate localized transdermal delivery while minimizing systemic exposure.
Here we report the use of a microfluidic reactor for the synthesis of DNVs and show that alteration of input parameters such
as flow speeds as well as molar and flow rate ratios increases entrapment efficiency of drugs and allows fine-tuning of DNV
size, elasticity, and surface charge. To determine the ability of DNV-encapsulated drug to be delivered transdermally to a local
site, we synthesized, characterized, and tested DNVs carrying the fluorescently labeled hydrophilic bisphosphonate drug AF-
647 zoledronate (AF647-Zol). AF647-Zol DNVs were lyophilized, resuspended, and applied topically as a paste to the calvarial
skin of mice. High-resolution fluorescent imaging and confocal microscopy revealed significant increase of encapsulated payload
delivery to the target tissue—cranial bone—byDNVs as compared to nondeformable nanovesicles (NVs) or aqueous drug solutions.
Interestingly, NVdelivery was not superior to aqueous drug solution. Our studies show thatmicrofluidic reactor-synthesizedDNVs
can be produced in good yield, with high encapsulation efficiency, reproducibility, and stability after storage, and represent a useful
vehicle for localized transdermal drug delivery.
1. Introduction
Transdermal application has numerous advantages as a route
for drug delivery, including—when patch application is
used—continuous delivery which results in stable drug levels,
ease of application, and elimination of the need for dosage
schedule adherence; perhaps most importantly, transdermal
delivery has resulted in a reduction in organ toxicity for some
drugs used chronically [1, 2]. The broad use of transdermal
delivery, however, has been limited by the requirements
for very specific physiochemical properties of the drug to
be delivered. However, recent advancements in transdermal
delivery including the use of microneedles [3], iontophoresis
[4], biopolymers/biomaterials [5, 6], and encapsulation of
drugs in liposomes—small (nano)synthetic vesicles compris-
ing a lipid bilayer (nanovesicles,NV)—have allowed progress.
Development of “elastic” deformable nanovesicles (DNVs)
[7, 8] in particular has been key to this progress.
Transdermal delivery, by definition, requires drug pas-
sage through the skin. Skin is an excellent protective bar-
rier, adept at preventing the entry of foreign substances,
ultraviolet radiation, and microbial or viral pathogens to the
body [9], a difficult barricade to breach for drug delivery.
A key feature of this barricade is the stratum corneum,
a layer of tightly packed, keratinized dead cells forming
the outermost component of the epidermis, which is about
10–40 𝜇m thick [10]. The only ingress across this layer is
through nanopore lacunae, which are approximately 50 nm
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or smaller, and even then requires facilitation to allow drug
entry [11]. Conventional NVs over this ∼50 nm size fail
to penetrate the stratum corneum and are thus excluded
from the deeper layers of the skin [12]. As postulated by
Cevc [13], DNVs synthesized with surfactant edge activators
are predicted to be elastic enough to deform and squeeze
through these nanopores without rupturing and leaking
their payload into the systemic circulation. It was further
postulated that hydration and osmotic forces were driving
these nanoparticles, which seek the deeper layers of the
skin for hydration. Cevc’s transfersomes and other subse-
quently developed deformable vesicles such as ethosomes
[7] (liposomes with a high concentration of ethanol) have
shown success in transdermal delivery, primarily for certain
lipophilic substances.
The conventional NV and DNV production methods
are often based around hand-mixing and postprocessing
involving sonication and/or extrusion and freeze-thawing.
It has been recognized that commonly used postprocessing
methods often compromise membrane integrity and com-
position and thus are unsuitable for use in encapsulation
of degradation-sensitive therapeutics. These methods have
also failed to be successful in encapsulating drugs of various
classes and solubilities in a defined, predictable manner.
Conventional synthesis methods are burdened with a lack of
reproducibility in vesicle size and drug entrapment efficiency,
which have critically hindered the clinical development of
NVs and DNVs [14–17].
A microfluidic-based NV production method may prove
to be a highly effective remedy for these technical issues.
Leaders in this burgeoning field include Jahn et al. [18, 19]
and Hood et al. [20, 21], who published recent studies on
microfluidic-enabled NV synthesis, hydrodynamic focusing,
and associated concepts. Within the narrow channels of a
microfluidic reactor chip, various membrane components
dissolved in specified ratios in organic and aqueous streams
as appropriate, at precisely controlled speeds and ratios,
are allowed to mix diffusively. The microscale dimensions
of these confined channels restrict turbulent flow, resulting
in well-defined mixing and homogenous, reproducible NV
populations. Moreover, the laminar flow patterns of the
microchannels can be predicted accurately and subjected
to mathematical modeling allowing for the manipulation of
micropatterned surface design. As the faster flowing aqueous
stream mixes with the organic stream, phospholipids are
thrown into an aqueous medium and assemble to form
unilamellar vesicles to establish thermodynamic stability and
in the process entrap any accompanying payload dissolved
in the streams. This powerful technique renders possible
encapsulation of a wide variety of drug classes, including
RNA, DNA, proteins, and both hydrophobic and hydrophilic
small molecules, without relying on destructive postprocess-
ing techniques to control size and lamerality.
In this study, we developed an adaptable synthesis
methodology for a DNV-based system using a commercially
available microfluidic reactor. Though the microfluidic reac-
tor chip used in this study was fabricated by and purchased
from a company, the base technology is simple and is being
used by an ever-expanding number of research groups [22,
23]. In our application, we present the encapsulation in
NVs and DNVs of a hydrophilic model drug, a fluores-
cently tagged bisphosphonate—AF647-zoledronate (AF647-
Zol)—with high efficiency, utilizing a modified method of
microfluidic synthesis. We further expanded on prior DNV
studies which focused their investigations on transdermal
penetration in vitro via Franz diffusion cell experiments [24]
to in vivo investigations in murine models. Our experimental
results show that cargo-loadedDNVs can successfully deliver
AF647-Zol through the skin barrier to an underlying target
tissue, in this case, bone. A delivery system capable of such a
task could reduce the amount of drug required for treatment
and have considerable implications in a number of fields
(albeit with different tissue targets), including dentistry [25],
pain management [26], wound healing [27], cosmeceuti-
cals, hair regrowth [28], tattoo removal [29], lymph node
targeting, and Langerhans cell-mediated immunotherapy
[30].
2. Materials and Methods
2.1. Preparation of a Dried Lipid Mixture. A dried lipid
mixture was synthesized by combining 1,2-dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC; Sigma Aldrich, St. Louis,
MO, USA), cholesterol (Sigma Aldrich, St. Louis, MO), and
N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium
methyl-sulfate (DOTAP; Avanti Polar Lipids, Alabaster, AL,
USA) as 10mM solutions in chloroform (Sigma Aldrich,
St. Louis, MO, USA) in a 5 : 3 : 2 volume ratio. DOTAP is
a cationic lipid commonly used as a cellular transfection
agent for nucleic acid delivery. Other lipid components
tested included the neutral lipid 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE; Sigma Aldrich, St. Louis,
MO, USA) or negatively charged diacetyl phosphate (DCP;
Sigma Aldrich, St. Louis, MO, USA) in place of DOTAP, with
DPPC and cholesterol in the same 5 : 3 : 2 ratio. Chloroform
was chosen as an initial step solvent due to its high solubility
potential for various lipid classes. The mixture was allowed
to dry by solvent evaporation under rotation for 5 minutes in
a Rotovap (Heidolph) or under ventilation for 48 hours.
2.2. Input Stream Preparation
2.2.1. Organic. The dried lipid mixture was resuspended and
dissolved in isopropyl alcohol (Sigma Aldrich, St. Louis, MO,
USA) in a volume equivalent to the chloroform initially
used before drying to maintain a lipid mix concentration of
10mM.
2.2.2. Aqueous. The aqueous stream comprised deionized
water filtered through a 0.22𝜇mmembrane Steriflip vacuum
setup (Millipore, Billerica, MA, USA). For compound/drug
loading, fluorescein isothiocyanate (FITC; ThermoFischer
Scientific, Waltham, MA, USA) or AF647-Zoledronate
(BioVinc LLC, Culver City, CA, USA) was loaded at a
concentration of 10–70 nM; theAF647-Zol concentrationwas
determined based on earlier studies involving intravenous
injection of AF647-Zol in animal models [31, 32].
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2.3. Microfluidic Reactor Setup. A Syrris microfluidic reactor
system (Royston, UK) was used for NV/DNV synthesis.
There are two input streams, here an aqueous one and
an organic one, each connected to its own pump. These
two pumps are connected to two separate liquid storage
containers of variable volumes, termed “loops.” The system
is running when setup is changed from “Fill” to “Inject”;
the contents of the loop are directed through microchannels
to the 26𝜇L reactor chip and exit through an outlet to a
collection tube. For DNV and NV synthesis, the membrane
components are dissolved in the organic stream and drug is
dissolved in the appropriate stream according to its solubility.
Depending primarily on the choice of drug to be loaded, one
of two synthesis strategies may be employed: the standard
approach or the modified method. For AF647-Zol, the mod-
ified method was used.
2.3.1. Standard Method: Low Speed and High Flow Rate
Ratio. The aqueous stream was pumped to the reactor at
1000 𝜇L/min and the organic stream was pumped to the
reactor at 10 𝜇L/min, for a resulting flow rate ratio of 100.
2.3.2. Modified Method: High Absolute Speed and Low Flow
Rate Ratio. The aqueous stream was pumped to the reactor
at 5000 𝜇L/min and the organic stream was pumped to the
reactor at 1000𝜇L/min, for a resulting flow rate ratio of 5.
Flow rate ratios of 7 and 10 were also tested, by setting
the aqueous stream to 7000 𝜇L/min and 10,000 𝜇L/min,
respectively.
2.4. Characterization
(i) Size and Dispersity. Samples of reactor-synthesized
NV/DNVs were diluted 10x and 100x in deionized water and
analyzed by the technique of dynamic light scattering on a
Malvern Zetasizer (Nano-ZS; Malvern, Worcestershire, UK)
at 25∘C.Threemeasurements, each averaging a hundred runs,
were performed on each sample, reported here as mean ±
standard deviation.
(ii) Zeta Potential. The surface charge of NV/DNV for-
mulations was assessed by zeta potential measurements by
dynamic light scattering under electrophoresis on a Malvern
Zetasizer (Nano-ZS: Malvern, Worcestershire, UK) at 25∘C.
Samples were diluted in 10x and 100x deionized water.
Three measurements, each averaging a hundred runs, were
performed on each sample, reported here asmean ± standard
deviation.
(iii) Entrapment Efficiency. Upon collection from the reactor,
sampleswere dialyzed in aG2 dialysis cassette (ThermoFisher
Scientific, Waltham, MA, USA) for 24 hours in a 1000-
fold dialysis volume. The dialysis solution was replaced at
12 h and 18 h. The dialyzed samples were probe sonicated
extensively for prolonged periods of time (Probe Solicitor;
Manufacturer) to rupture vesicle membranes and release
the content. The drug content of the ruptured sample was
quantified by fluorescent spectroscopy (for FITC and AF647-
Zol).
(iv) AFM Analysis. All atomic force microscopic (AFM)
measurements of the nanovesicles were done under ambi-
ent conditions after absorption on a mica surface using
a Dimension Icon AFM (Bruker Corporation, CA). AFM
measurements were collected in tapping mode using silicon
cantilevers (TESPW, Bruker) at 1Hz and 256 samples/line.
The height, amplitude, and phase were obtained for the
AF647-Zol DNVs and conventional NVs. Images were plane
fit using Nanoscope software (version 9.0).
2.4.1.Morphology by Transmission ElectronMicroscopy. Sam-
ples of NVs and DNVs loaded with AF647-Zol produced
by the modified microfluidic method were diluted 500x,
absorbed onto a copper mesh (EMScience, Cat #FCF400-
Cu) for 18 minutes, and fixed with glutaraldehyde for 3
minutes. Following a wash, they were stained with uranyl
acetate solution for 3 minutes. They were then imaged on a
JEOL 100CX electron microscope at 58,000 to 100,000 times
magnification.
2.4.2. Confocal Microscopy. Samples of DNVs loaded with
AF647-Zol produced by the modified microfluidic method
were dialyzed and lyophilized as described below. The
lyophilized samples were then resuspended to a 100x dilution
of their original postsynthesis concentration. Resuspended
samples were imaged in fluid on a glass slide through an SP5
Leica Confocal Microscope (Leica Microsystems, Waltzer,
Germany) to determine postlyophilization vesicle viability
and drug leakage.
2.5. Storage and Preparation for In Vivo Application: Dialysis,
Lyophilization, and Resuspension. Upon collection from the
reactor, samples were dialyzed in a G2 dialysis cassette (Ther-
moFisher Scientific, Waltham, MA, USA) for 24 hours in a
1000-fold dialysis volume. The dialysis solution was replaced
at 12 h and 18 h. The NVs/DNVs were then lyophilized
(Labconco, Kansas City, MO) for 24 hours until they were
converted to a powder. For in vivo application to murine
calvarial skin, the lyophilized formulations were resuspended
in 0.9% saline to a thick liquid paste-like consistency, concen-
trated 150-fold from postsynthesis concentration.
2.6. In Vivo Trial Experimental Design. Thirteen C57Bl6J
wildtype mice were divided into three groups of four rep-
resenting topical treatment with (i) AF647-Zol-loaded DNV
paste, (ii) AF647-Zol-loaded NV paste, or (iii) aqueous
solution of AF647-Zol, with the remaining mouse receiving
only 0.9% saline as a negative control.
Prior to topical application, each of the thirteen mice
had the hair on their calvarial skin shaved by a maxillofacial
surgeon with great care taken to prevent injury or scratches.
The mice were then anesthetized by isoflurane inhalation
and the appropriate formulation was applied topically and
unoccluded on the calvarial skin above the skull and spread
in a square pattern. The mice remained anesthetized for
an hour following application to prevent grooming-related
drug removal. Mice were sacrificed 48 hours later by CO
2
inhalation followed by cervical dislocation, and their skull,
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calvarial skin, and (right or left) femur were extracted and
analyzed through several fluorescent analysis techniques
to ascertain the efficacy of penetration and drug delivery.
All animal experiments were performed with a protocol
approved by the Animal Research Oversight Committee and
in accordancewith all the rules and regulations for animal use
and care at UCLA.
2.7. Tissue Dissection and Analysis. The extracted skull,
femur, and calvarial skin surface were imaged by an LAS3000
luminescent image analyzer (Fujifilm, Tokyo, Japan). In each
skull image, the standardized circular area centered by the
intersection between the coronal suture and the sagittal
suture was determined as the region of interest (ROI). The
total AF647 intensity in the ROI was measured using an
open source, Java-based image processing program (ImageJ,
https://imagej.nih.gov/ij/, NIH, Bethesda, MD). The mean
and standard deviation were calculated in each group and
compared by Dunnett’s test. The statistical significance was
reached at 𝑝 < 0.05.
Portions of the extracted skin and skull bone were fixed
in 70% ethanol and sectioned and stained with hematoxylin
and eosin to analyze histology. The skin and skull bone
were also cryosectioned and mounted with a fluorescence-
protective media with DAPI. These cryosectioned samples
were analyzed by confocal laser scanning microscopy to dis-
cern the depth and degree to which the different formulations
permeated through the layers of the skin and deposited the
payload to the underlying target site.
3. Results and Discussion
3.1. Formulation of NVs and DNVs. The method parameters
used here for NV/DNVs were chosen through rational con-
sideration of the components, review of existing literature,
and testing. 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine
(DPPC), a tried and tested phospholipid that is inexpensive
and readily available, was the primary component of the lipid
mixture at 50mol% (w/w). Cholesterol was chosen as the
second component of the lipidmixture at 30mol% (w/w), as it
is an integral component of biological membranes and a well-
known regulator of membrane fluidity and rigidity at physi-
ological temperature and pH. To control the surface charge,
we chose a positively charged N-[1-(2,3-dioleoyloxy)propyl]-
N,N,N-trimethylammonium methyl-sulfate (DOTAP), neg-
atively charged diacetyl phosphate (DCP), and neutral
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), to
make up the remainder of the lipid mixture.
The lipid mixture described above was exactly the same
for both NVs and DNVs. For the synthesis of DNVs, the
only difference is the addition of an edge activator to the
above lipid mixture. For this purpose, sorbitan monooleate
(Span 80), a nonionic surfactant that is a GRAS material,
was added to the mixture at 15% (w/w), which was previously
reported to be an optimum edge activator/concentration for
skin penetration in in vitro Franz diffusion cell experiments
[24]. Span 80 was chosen based on its biocompatibility and
low HLB number (∼3.4), which allows it to intercalate well
within the membrane and exert its surface tension-reducing
properties, thus destabilizing the membrane and increasing
its elasticity.
3.2. Salient Properties of Microfluidic Reactor-Produced
NVs and DNVs
3.2.1. Microfluidics Reaction Principle. When phospholipid
molecules are dispersed in aqueous solution, thermodynamic
forces induce them to self-assemble into aggregates to mini-
mize the Gibb’s free energy. Due to their amphiphilic struc-
ture, this stable aggregate is vesicular and is either micellar
or bilayered. In microfluidic production, lipids contained
in a slow-flowing organic solvent (isopropanol for example)
that is miscible with water are mixed with a much faster
flowing aqueous solution and thus are forced to quickly
aggregate into vesicles, entrapping the aqueous solution and
whatever is contained in it.Microfluidics additionally exploits
the properties of flow through narrow channels confined to
microscale dimensions in which diffusive mixing is signifi-
cant and turbulent flow is minimized. The narrow channels
and limited residence time result in unilamellar as opposed
to multilamellar vesicles. The laminar flow eliminates most
of the chaotic mixing, resulting in predictable and repro-
ducible flow patterns that may be accurately characterized
and modeled mathematically. The reproducibility afforded
by this strategy is unachievable by conventional synthesis
methods. In terms of production, this use is extended by
eliminating the need for subsequent sample postprocessing
such as sonication, extrusion, and freeze-thawing, all of
which consume time, require additional equipment, and
perhaps most importantly compromise membrane integrity
and involve destruction and reformation of the vesicles [33].
3.2.2. Size and Dispersity. We first determined optimal con-
ditions for NV and DNV synthesis using fluorescein isoth-
iocyanate (FITC) as an aqueous payload. The diameters of
NVs and DNVs generated by the microfluidic methods we
used here and loaded with FITC are reported in Table 1 as
nanometer (nm)mean +/− standard error of themean (sem).
In all cases, NV formulations were quite homogenous in size,
consistently showing polydispersity index values of 0.1 to 0.2.
Regarding trends in microfluidic parameters and resultant
size, we found that increasing the flow rate ratio (FRR)
resulted in smaller vesicle sizes. Additionally, for fixed input
parameters, smaller volume microfluidic chips produced
smaller vesicles. Reducing the lipid mixture concentration in
the organic stream additionally lowered the vesicle size.
NV size is perhaps the single most important factor
for effective drug delivery by many routes [34, 35] and
this is especially the case for transdermal delivery [36,
37]. As mentioned earlier, the limiting factor to NV-based
transdermal drug delivery is transport across the stratum
corneum, the main functional barrier and the outermost
layer of the epidermis. The stratum corneum is formed of
tightly packed corneocytes (nonviable keratinocytes that have
reached terminal differentiation) which are embedded in
membranous extracellular lipid structures. As protein bridges
called corneodesmosomes between corneocytes degrade,
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Table 1:Characteristics of FITC-loadedDNVs/NVs generated by the standard andmodifiedmethods. DNVs loadedwith FITCwere synthesized
using a standard microfluidic method using a relatively fast aqueous flow rate (1000𝜇L/min) and slow organic flow rate (10 𝜇L/min) and
thus a FRR of 100. In the modified method, the aqueous pump rate was to 5000 𝜇L/min and organic 1000𝜇L/min, for a resulting FRR of
5. Conventional (nondeformable) NVs were synthesized by the standard method. The resultant diameters by either method or type of NVs
(deformable; nondeformable) were similar, withNVs at 196± 39 nm,DNVs by the standardmethod at 202± 17 nm, andDNVs by themodified
method at 221 ± 41 nm. Zeta potentials were also similar with DNV standard > DNV modified > NV standard. Entrapment efficiency was
greatly impacted by method for DNVs, with efficiency being much higher with the modified method for DNVs; entrapment efficiency was
similar for modified-method DNVs and conventional NVs.
Nanovesicle (NV)
type
DNVs synthesized by standard
microfluidic method
(low IPA speed; high FRR)
DNVs synthesized by
modified microfluidic
method
(high speed; low FRR)
Conventional NVs
Characteristics
Size (diameter) 202 ± 17 nm 221 ± 40 nm 196 ± 39 nm
Zeta potential 46 ± 2.4mV 41.7 ± 3.7mV 38.1 ± 1.8mV
Entrapment efficiency (FITC dye) 1.1% 39.6% 37.4%
intercellular pathways are formed in the stratum corneum
[38, 39], which are on the order of 50 nm in diameter [40].
This extracellular pathway allows ingress through the stratum
corneum. The transfollicular pathway comprising the space
around the hair shaft is another available route, though this
path does not reliably provide for delivery of significant
amounts of therapeutic. Conventional NVs are unable to
cross through the pores, rupturing as they squeeze through
and leaking out payload; very small NVs of less than 50 nm
have, however, been shown to have moderate success. NVs at
and under this size are quite difficult to produce in sufficient
quantity and have limited drug-loading capacity. However,
DNV formulations, even at sizes greater than 200 nm, are able
to squeeze through the lacunar domains, maintain integrity
and payload, and reach the target site.
3.2.3. Zeta Potential. The zeta potential of an NV is its overall
charge in a particular vehicle and, in addition to size, has
a great influence on particle penetrance [36]. Zeta potential
has implications in passive targeting of the NVs, as well as
NV stability in solution. The measured zeta potentials are
reported in Table 1 as mean ± sem. In addition, we compared
positively charged DOTAP to two other lipids: DCP which
is negatively charged and DOPE, which is neutral. The zeta
potentials were +41.7 ± 3.7mV (DOTAP), −23.9 ± 5.6mV
(DCP), and +7.2 ± 1.9mV (DOPE) for DNVs, showing the
tunable nature of vesicle charge by incorporation of different
phospholipids.
Zeta potential plays a role in the colloidal stability of
NVs: a sufficiently high zeta potential (reported in some
studies as ±30mV) allows NVs to repel each other in solution
and thus prevent or slow down the rate of flocculation and
aggregation [41, 42]. In addition, the development of NVs
and DNVs with different zeta potentials should expand the
clinical application to a wide range of tissues with various cell
surface charges.
3.3.TheModifiedMicrofluidic Methods Significantly Improved
NV/DNV Drug Encapsulation. NVs/DNVs are formed upon
mixing of organic components and aqueous solution,
typically by utilizing a relatively fast-flowing (1000 𝜇L/min)
aqueous stream and a slower flowing (10 𝜇L/min) organic
stream containing the lipid components dissolved in iso-
propyl alcohol (IPA) to give a high FRR of 100.This is suitable
for the encapsulation of hydrophobic drugs, which accom-
pany the membrane components in the organic stream and
are thus easily embedded in the membrane upon vesicle for-
mation when the streamsmix. Unfortunately, for hydrophilic
drugs, this method is largely ineffective as indicated by the
low entrapment efficiency presented in Table 1. Hydrophilic
drugs that exhibit good solubility in aqueous solvent must
be dissolved in the fast-flowing aqueous solution loop; as
a result, during the rapid mixing and vesicle formation
process, most the drug does not have a chance to become
entrapped within the aqueous core of the NVs and a majority
of drug flows past the lipids and into the collection tube
unencapsulated.
To overcome this limitation, our group developed a
modified microfluidic synthesis strategy to encapsulate
hydrophilic drugs. We considered that using an aqueous
streammoving at a speed 5 times faster relative to the organic
stream instead of a speed 100 times faster would result in
a dramatically higher amount of hydrophilic drug being
entrapped.Though this would result in the mix solution con-
taining 16.7% IPA as opposed to the 1% IPA in the standard
case, we surmised that this would not adversely affect NV
formation, as other existing techniques, such as the reverse
phase ethanol evaporation technique, are quite successful in
NV production despite the large initial quantities of ethanol
[43]. Realizing that the reduction of FRR in the new method
would potentially sacrifice homogeneity and increase the size
and dispersity of the resulting population, we rationalized
that ramping up the absolute speeds of both the aqueous
and organic streams while keeping the FRR fixed at 5 could
rescue some of the deleterious effects of a lower FRR. For this
method, we tested various low FRRs and absolute speeds and
settled on an optimum of the lipid-containing IPA stream
moving at 1000 𝜇L/min and the aqueous stream moving at
5000 𝜇L/min. The characteristics of DNVs produced by the
standard method and the modified method are compared in
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Table 2: Characteristics of AF647-Zol-loaded DNVs/NVs. AF647-loaded NVs and DNVs were prepared in the microfluidic reactor using the
modified method. DNVs were slightly larger in diameter than NVs and also had a greater zeta potential.
Type DNVs Conventional NVs
Characteristics
Size (diameter) 236 ± 62 nm 204 ± 47 nm
Zeta potential 33.8 ± 3.5mV 29.2 ± 1.4mV
Table 1. As expected, the populations synthesized through
the modified method show a modest increase in size and
dispersity, a small price to pay for much greater entrapment
efficiency. An additional benefit of themodifiedmethod is the
vast reduction in total reaction time and increase in resultant
DNV concentration, which may be favorable in scaling up
production.
A similar outcome to the modified method in terms of
hydrophilic drug entrapment could potentially be obtained
by the addition of a third inlet stream, with a slow-flowing
aqueous solution of the hydrophilic drug meeting the other
two streams within the reactor channels.
3.4. In Vivo Testing of Transdermal Delivery of AF647-
Zol-Loaded NVs and DNVs. To demonstrate transdermal
delivery and localized payload release, we selected the mouse
head skin as the target transdermal tissue, closely overlaying
the calvarial bone. We strategized to entrap a fluorescently
labeled bisphosphonate (AF647-Zol), which has a significant
affinity tomineralized tissue andwould be stably absorbed on
the surface of bone. The postulated transdermal penetration
and the local payload release could be monitored by the
fluorescent signal of AF647-Zol adsorbed on the surface of
calvarial bone.
3.4.1. Synthesis of AF647-Zol Loaded NVs and DNVs. The
reactor-based modified method described above was used
to synthesize NVs and DNVs encapsulating AF647-Zol for
the purpose of determining localized transdermal delivery to
underlying bone. Since skin layers are known to be negatively
charged [44], positively charged vesicles have been shown
to improve penetration and retention in the skin [45–47].
It is therefore theorized that NVs as well as DNVs having a
positive surface chargemay fare better in terms of penetration
into and retention in the skin as compared to similar neutral
or negatively charged NVs [48, 49]. For this project, we
synthesized positively charged NVs and DNVs (Figure 1(a)).
The overall schematic for production and application of
AF647-Zol NV/DNV (and unencapsulated aqueous AF647-
Zol) is shown in Figure 1(b). The reactor-produced NVs and
DNVs were lyophilized and stored before use.
3.4.2. Stability. The ability of reactor-produced NV/DNVs
to withstand processing techniques for storage, primarily
lyophilization, is critical in determining their shelf life, phar-
maceutical utility, and transportability. Our investigations
suggest that DNVs have long term stability after lyophiliza-
tion and indeed show minimal drug leakage, as shown in
Figure 2(d). DNVs loaded with AF647-Zol synthesized by
the modified microfluidic method were subject to dialysis
to remove free drug from solution and then lyophilized to
a powder. Two weeks following resuspension in deionized
water, they were imaged by confocal microscopy. The images
clearly show that the fluorescence is contained only in
the spherical vesicle structures and not found diffusely in
solution suggesting that the membrane integrity was not
compromised during the lyophilization and resuspension
process and that drug leakage did not occur. Furthermore,
confocal microscopy indicates the sizes after lyophilization
correlate quite well with initial measurements obtained prior
to lyophilization through dynamic light scattering (Table 2).
3.4.3. Characteristics of AF647-Zol NV/DNVs. As shown in
Table 2, the size and zeta potential were very similar to
the NV/DNVs encapsulating FITC in the prestudy method
development.
3.4.4. Morphology and Deformability. The morphology of
microfluidic-produced AF647-Zol-loaded NV/DNVs was
studied through fixation, negative staining, and transmission
electron microscopy. Representative micrographs of 500x
diluted, drug-loaded samples out of the reactor chip are
presented in Figures 2(a), 2(b), and 2(c). The images show
spherical and globular vesicle structures for NV/DNVs syn-
thesized by a standard method and DNVs synthesized by a
modified method. NV/DNVs were roughly 240 nm in size.
This size measured from electron microscopy differs from
that obtained by dynamic light scattering not only because
the techniques utilize different principles but also because
electron microscopy requires fixation, adherence, and drying
of the vesicles on a membrane, which flattens them and may
artificially increase size.
The atomic force microscopic (AFM) analysis revealed
the similar uniform spherical morphology of AF647-Zol-
loaded NVs and DNVs in the height images (Figures 3(a)
and 3(d), resp.) as well as the amplitude error images (Figures
3(b) and 3(e), resp.). However, the phase image of AF647-Zol-
loaded NVs and DNVs differs significantly (Figures 3(c) and
3(f), resp.). Phase imaging monitoring the phase lag between
signals can be used to map variations in surface properties
such as elasticity. While quantitative measurements were not
obtained, the deformable features of DNVs as compared
to NVs were clearly indicated. The higher phase contrast
observed in phase imaging of the DNVs (Figure 3(f)) as com-
pared to conventional NVs indicates increased deformability
of the nanovesicles.
3.4.5. TransdermalDelivery of AF-Zol Bisphosphonate andTis-
sue Distribution. The proof-of-concept demonstration of the
enhanced capability of the microfluidic-produced DNVs to
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Figure 1: Synthesis and testing of drug-loaded conventional and deformable NVs. Synthesis took place in a 26 𝜇L volumemicrofluidic chamber,
wherein controlled and confined laminar diffusivemixing of aqueous AF647-Zol (upper right, 1(a)) solution and lipidmembrane components
dissolved in isopropyl alcohol occurs within the microchannels and results in the formation of homogenous, reproducible populations of
drug-loaded NVs, which may be made deformable by addition of the edge activator sorbitan monooleate (Span 80). The drug-loaded NVs
andDNVs underwent dialysis, lyophilization, and resuspension before application to shaved calvarial skin of wildtype C57Bl6Jmice. Aqueous
solution of free AF647-Zol was also used. Deformable NVsmore readily penetrate the outer dermis (upper dermal image) through nanopores
without rupturing which may occur with conventional NVs (lower image, 1(b)) and releasing cargo before reaching the target.
deliver a drug payload transdermally compared to theNVs or
vehicle was done by application of the vesicles in a paste to the
shaved head skin of mice. After transdermal application, the
fluorescentAF647-Zol signal from the target tissue—calvarial
bone—was the greatest for DNVs (Figure 4(a)) compared
to the NVs (Figure 4(b)) and the application of AF647-Zol
aqueous solution (Figure 4(c)). The anatomy of the calvarial
area is shown in Figure 4(d), and the signals quantified are
shown in Figure 4(e), revealing the increase with AF647-Zol-
DNV to be significant (𝑝 < 0.05).
The DNVs, therefore, had the greatest success transvers-
ing the stratum corneum and remaining skin layers and
8 Journal of Drug Delivery
(a)
(b)
(c)
(d)
(e)
1휇m
Figure 2: Transmission electron and confocal micrographs of AF647-Zol-loaded NV/DNVs synthesized in a microfluidic reactor. Shown are (a)
a conventional NV and (b) an AF647-Zol-loaded DNV, both produced by our modified microfluidic method, viewed at 72,000x. In (c), an
AF647-Zol-loaded DNV produced by the standard microfluidic method that underwent lyophilization, storage at 277K, and resuspension
produced by the regular microfluidic method is viewed at 100,000x. Images were obtained using a uranyl acetate stain and copper mesh
background on a JEOL 100CX transmission electron microscope. Estimated diameters are (a) 246 nm, (b) 241 nm, and (c) 298 nm. Colloidal
solutions of AF647-Zol-loaded NVs and DNVs in (d) and (e), respectively, were imaged by confocal laser microscopy using a Leica TCS SP5
microscope following dialysis, lyophilization, and resuspension. The largest DNV depicted is estimated to be ∼400 nm in diameter, and the
vesicles are quite homogenous in size. The fluorescent drug is contained only within the NVs and DNVs and is not in solution, confirming
stability.
delivering the drug to the bone. DNVs also provided themost
consistent results, in terms of degree of staining, which was
very similar for allmice in that group.Cryosectioned calvarial
bone counterstained with DAPI (labeling nuclei) and imaged
by confocal laser scanning microscopy (CLSM) showed the
uniform AF647-Zol signal on the external bone surface
interfacing the dermal tissue for DNV delivery (Figure S3C
in SupplementaryMaterial available online at https://doi.org/
10.1155/2017/4759839), suggesting the local payload release
within the dermal tissue.
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Figure 3: Atomic force microscopy of AF647-Zol-loaded NVs and DNVs. The height, amplitude error, and phase are shown for conventional
NVs ((a), (b), and (c), resp.) and DNVs ((d), (e), and (f), resp.). The higher phase contrast in DNVs in (f) indicated by blue arrows compared
to conventional NVs (c) suggests higher deformability of the vesicles under the same applied imaging force.
3.4.6. Subcutaneous Localization. The luminescent analyzer
images of the outer surface of the calvarial skin, where
the formulations were applied, are presented in Figure S2.
To further understand the fate of the drug in the skin,
we cryosectioned the excised calvarial skin, stained with
DAPI, and examined the samples through CLSM. Both
the DNVs and NVs (A, B) show notable follicular affinity,
particularly as compared to the aqueous solution (C). DNVs
show the highest retention within the skin layers, which
may indicate increased skin adherence and thus resistance
against rodent grooming and licking behavior. Two forces
that may contribute to rupture of NVs and DNVs to release
their drug payload in the deeper epidermal and dermal
layers are the osmotic pressure gradient and interactions with
the embedded lipid membranes and subcutaneous fat. Our
data suggests that DNVs withstand these forces better than
NVs.
3.4.7. Systemic Leakage. AF647-Zol is a bone-targeting drug
that labels any bone (specifically, calcium depot) with which
it comes in contact. Thus femur bones were collected from
mice in in vivo trials and imaged to assess the degree of
systemic leakage resulting from each applied formulation.
These results, presented in Figure S1, show that there is some
degree of systemic drug leakage when the aqueous solution
is applied, which is less when the drug is encapsulated in
DNVs.
4. Conclusion
In this series of investigations, we have presented the devel-
opment of an adaptable transdermal drug delivery system
based on microfluidic-produced DNV technology. Lipid
nanoparticle technology, which is well-characterized and
mature, may at long last realize its full potential via the
enabling microfluidic platform which overcomes a multitude
of existing barriers to reproducibility, tunability for size, and
scalable synthesis and has the potential to pave the way for
the next generation of nanovesicle-based pharmaceuticals to
reach the clinic. To enable loading of various drug classes and
polarities and thus expand the utility of this drug delivery
system, we developed a modified microfluidic method to
overcome technical challenges in encapsulating significant
quantities of hydrophilic molecules by altering the flow
speeds and relative flow ratios of the component-containing
streams fed into the reactor chip.
In a murine model, we have shown proof-of-concept for
transdermal drug delivery using the microfluidic-produced
10 Journal of Drug Delivery
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Figure 4:AF647-Zol calvarial bone distribution.The AF647-Zol signal is the greatest with DNV delivery (a) of the 3 methods used.The signal
is reduced with either conventional NV delivery (b) or delivery of free aqueous AF647-Zol (c); in fact aqueous delivery appears to be slightly
more effective than NV delivery.The skull anatomy is shown with the region of interest (ROI) circled (d). AF647 signal levels in the ROI were
quantified (e), revealing DNV delivery is significantly (∗𝑝 < 0.05) greater than either NV or aqueous delivery.
DNVs carrying the bisphosphonate drug zoledronate which
outperform conventional NVs and aqueous drug solutions in
delivering payload to underlying bone.
The tunability of the DNV size in the microfluidic system
could enable expanded utility of the DNVs from transdermal
to topical drug delivery systems. By slowing down the
flow speeds and increasing DNV size, larger DNVs can be
generated. Larger DNVs tend to aggregate and be retained
in the epidermal and dermal layers, releasing their payload
upon fusion with the extracellular lipid membranes present
in those layers. A similar strategy may enable the technology
to be used successfully in transmucosal delivery. Transport
through mucosal membranes presents similar advantages to
transdermal delivery but requires different features: larger
vehicles with a high molecular weight and high charge to
resist being washed away and be more effectively retained in
the mucosa.
While the current microfluidic system offers a number of
remarkably useful advantages suitable for large scale produc-
tion ofDNVs, we believe that we can continue to optimize the
synthesis conditions such as mixing of the streams, which is
currently confined to diffusion. We will continue to explore
temperature and pressure changes and possibly use acoustic
energy applied to the microfluidic reactor as part of this
process. The eventual goal is to encapsulate hydrophobic as
well as hydrophilic drugs and thus expand the therapeutic
landscape of candidate molecules that could be used for
human disorders.
Disclosure
Ichiro Nishimura and Varghese John share co-senior author-
ship.
Conflicts of Interest
The authors declare that there are no conflicts of interest
regarding the publication of this article.
Acknowledgments
The authors would like to thank Advanced Light Microscopy
Services and Keyence for confocal microscopy support; the
Brain Research Institute for access to transmission electron
microscopy; the Wu Lab in the UCLA Department of Bio-
engineering for access to the Zetasizer; Kaley Powers, Bache-
lor of Fine Arts degree student at UCLA for Figure 1; and the
UCLADepartment of LaboratoryAnimalMedicine (DLAM)
for housing the mice used in the studies. They acknowledge
the use of AFMs at the Nano and Pico Characterization
Laboratory at California NanoSystems Institute. This work
was conducted in part in a facility supported by NIH/NCRR
Research Improvement Program Grant C06 RR014529. They
would like to acknowledge the funding support from the
Mary S. Easton Center for Alzheimer’s Disease Research to
the DDL and the NIH/NIDCR Grants R01 DE022552 (to
Ichiro Nishimura) and R21 DE023410 (to Ichiro Nishimura).
Journal of Drug Delivery 11
References
[1] A. C. Watkinson, M.-C. Kearney, H. L. Quinn, A. J. Courtenay,
and R. F. Donnelly, “Future of the transdermal drug delivery
market—have we barely touched the surface?” Expert Opinion
on Drug Delivery, vol. 13, no. 4, pp. 523–532, 2016.
[2] R. Langer, “Transdermal drug delivery: past progress, current
status, and future prospects,” Advanced Drug Delivery Reviews,
vol. 56, no. 5, pp. 557–558, 2004.
[3] R. K. Sivamani, D. Liepmann, andH. I.Maibach, “Microneedles
and transdermal applications,” Expert Opinion on Drug Deliv-
ery, vol. 4, no. 1, pp. 19–25, 2007.
[4] M. Roustit, S. Blaise, and J.-L. Cracowski, “Trials and tribula-
tions of skin iontophoresis in therapeutics,” British Journal of
Clinical Pharmacology, vol. 77, no. 1, pp. 63–71, 2014.
[5] Y. Chen, M. Wang, and L. Fang, “Biomaterials as novel pen-
etration enhancers for transdermal and dermal drug delivery
systems,” Drug Delivery, vol. 20, no. 5, pp. 199–209, 2013.
[6] K. H. Basavaraj, G. Johnsy, M. A. Navya, R. Rashmi, and Sid-
daramaiah, “Biopolymers as transdermal drug delivery systems
in dermatology therapy,” Critical Reviews in Therapeutic Drug
Carrier Systems, vol. 27, no. 2, pp. 155–185, 2010.
[7] K. Ita, “Current status of ethosomes and elastic liposomes in
dermal and transdermal drug delivery,”Current Pharmaceutical
Design, vol. 22, no. 33, pp. 5120–5126, 2016.
[8] R. Raj, P. M. Raj, and A. Ram, “Lipid based noninvasive vesic-
ular formulation of cytarabine: nanodeformable liposomes,”
European Journal of Pharmaceutical Sciences, vol. 88, pp. 83–90,
2016.
[9] Y. Belkaid and S. Tamoutounour, “The influence of skin
microorganisms on cutaneous immunity,” Nature Reviews
Immunology, vol. 16, no. 6, pp. 353–366, 2016.
[10] A. Bo¨hling, S. Bielfeldt, A. Himmelmann, M. Keskin, and K.-
P. Wilhelm, “Comparison of the stratum corneum thickness
measured in vivo with confocal Raman spectroscopy and
confocal reflectancemicroscopy,” Skin Research and Technology,
vol. 20, no. 1, pp. 50–57, 2014.
[11] S. J. Jiang and X. J. Zhou, “Examination of the mechanism of
oleic acid-induced percutaneous penetration enhancement: an
ultrastructural study,” Biological and Pharmaceutical Bulletin,
vol. 26, no. 1, pp. 66–68, 2003.
[12] R. R. Hood, E. L. Kendall, M. Junqueira et al., “Microfluidic-
enabled liposomes elucidate size-dependent transdermal trans-
port,” PLoS ONE, vol. 9, no. 3, Article ID e92978, 2014.
[13] G. Cevc, “Rational design of new product candidates: the next
generation of highly deformable bilayer vesicles for noninva-
sive, targeted therapy,” Journal of Controlled Release, vol. 160, no.
2, pp. 135–146, 2012.
[14] A. Akbarzadeh, R. Rezaei-Sadabady, S. Davaran et al., “Lipo-
some: classification, preparation, and applications,” Nanoscale
Research Letters, vol. 8, no. 1, article 102, 2013.
[15] S. Batzri and E. D. Korn, “Single bilayer liposomes prepared
without sonication,” Biochimica et Biophysica Acta—Biomem-
branes, vol. 298, no. 4, pp. 1015–1019, 1973.
[16] J. Dua, A. Rana, and A. Bhandari, “Liposome: methods of
preparation and applications,” International Journal of Pharma-
ceutical Studies and Research, vol. 3, pp. 14–20, 2012.
[17] J. D. Castile and K. M. G. Taylor, “Factors affecting the size
distribution of liposomes produced by freeze-thaw extrusion,”
International Journal of Pharmaceutics, vol. 188, no. 1, pp. 87–95,
1999.
[18] A. Jahn, S.M. Stavis, J. S.Hong,W.N.Vreeland,D. L.Devoe, and
M.Gaitan, “Microfluidicmixing and the formation of nanoscale
lipid vesicles,” ACS Nano, vol. 4, no. 4, pp. 2077–2087, 2010.
[19] A. Jahn, W. N. Vreeland, D. L. Devoe, L. E. Locascio, and
M. Gaitan, “Microfluidic directed formation of liposomes of
controlled size,” Langmuir, vol. 23, no. 11, pp. 6289–6293, 2007.
[20] R. R.Hood andD. L.Devoe, “High-throughput continuous flow
production of nanoscale liposomes bymicrofluidic vertical flow
focusing,” Small, vol. 11, no. 43, pp. 5790–5799, 2015.
[21] R. R. Hood, C. Shao, D. M. Omiatek, W. N. Vreeland, and
D. L. Devoe, “Microfluidic synthesis of PEG- and folate-
conjugated liposomes for one-step formation of targeted stealth
nanocarriers,” Pharmaceutical Research, vol. 30, no. 6, pp. 1597–
1607, 2013.
[22] B. Yu, R. J. Lee, and L. J. Lee, “Microfluidic methods for
production of liposomes,”Methods in Enzymology, vol. 465, pp.
129–141, 2009.
[23] N. Hassan, F. Oyarzun-Ampuero, P. Lara et al., “Flow chemistry
to control the synthesis of nano andmicroparticles for biomedi-
cal applications,” Current Topics in Medicinal Chemistry, vol. 14,
no. 5, pp. 676–689, 2014.
[24] A. Salimi, N. Hedayatipour, and E. Moghimipour, “The effect of
various vehicles on the naproxen permeability through rat skin:
a mechanistic study by DSC and FT-IR techniques,” Advanced
Pharmaceutical Bulletin, vol. 6, no. 1, pp. 9–16, 2016.
[25] G. Tiwari, R. Tiwari, S. Bannerjee et al., “Drug delivery systems:
an updated review,” International Journal of Pharmaceutical
Investigation, vol. 2, no. 1, pp. 2–11, 2012.
[26] P. M. Finch and P. D. Drummond, “Topical treatment in
pain medicine: from ancient remedies to modern usage,” Pain
Management, vol. 5, no. 5, pp. 359–371, 2015.
[27] N. Monteiro, A. Martins, R. L. Reis, and N. M. Neves, “Lipo-
somes in tissue engineering and regenerativemedicine,” Journal
of the Royal Society Interface, vol. 11, no. 101, Article ID 20140459,
2014.
[28] S. Mura, F. Pirot, M. Manconi, F. Falson, and A. M. Fadda,
“Liposomes and niosomes as potential cariers for dermal
delivery of minoxidil,” Journal of Drug Targeting, vol. 15, no. 2,
pp. 101–108, 2007.
[29] M. Ramirez, N. Magee, D. Diven et al., “Topical imiquimod as
an adjuvant to laser removal of mature tattoos in an animal
model,” Dermatologic Surgery, vol. 33, no. 3, pp. 319–325, 2007.
[30] D. Oosterhoff, B. J. R. Sluijter, B. N. Hangalapura, and T. D.
De Gruijl, “The dermis as a portal for dendritic cell-targeted
immunotherapy of cutaneous melanoma,” Current Topics in
Microbiology and Immunology, vol. 351, no. 1, pp. 181–220, 2012.
[31] A. Hokugo, R. Christensen, E. M. Chung et al., “Increased
prevalence of bisphosphonate-related osteonecrosis of the jaw
with vitamin D deficiency in rats,” Journal of Bone and Mineral
Research, vol. 25, no. 6, pp. 1337–1349, 2010.
[32] A. Hokugo, S. Sun, S. Park, C. E. McKenna, and I. Nishimura,
“Equilibrium-dependent bisphosphonate interactionwith crys-
talline bone mineral explains anti-resorptive pharmacokinetics
and prevalence of osteonecrosis of the jaw in rats,” Bone, vol. 53,
no. 1, pp. 59–68, 2013.
[33] L. A. Morton, J. P. Saludes, and H. Yin, “Constant pressure-
controlled extrusion method for the preparation of Nano-sized
lipid vesicles,” Journal of Visualized Experiments : JoVE, no. 64,
2012.
[34] J. Qi, Y. Lu, and W. Wu, “Absorption, disposition and
pharmacokinetics of solid lipid nanoparticles,” Current Drug
Metabolism, vol. 13, no. 4, pp. 418–428, 2012.
12 Journal of Drug Delivery
[35] S. Salatin, S. Maleki Dizaj, and A. Yari Khosroushahi, “Effect of
the surface modification, size, and shape on cellular uptake of
nanoparticles,” Cell Biology International, vol. 39, no. 8, pp. 881–
890, 2015.
[36] N. R. Khan,M. S. Harun, A. Nawaz, N. Harjoh, and T.W.Wong,
“Nanocarriers and their actions to improve skin permeability
and transdermal drug delivery,”Current Pharmaceutical Design,
vol. 21, no. 20, pp. 2848–2866, 2015.
[37] C. Pegoraro, S. MacNeil, and G. Battaglia, “Transdermal drug
delivery: frommicro to nano,”Nanoscale, vol. 4, no. 6, pp. 1881–
1894, 2012.
[38] H. Trommer and R. H. H. Neubert, “Overcoming the stratum
corneum: the modulation of skin penetration. A review,” Skin
Pharmacology and Physiology, vol. 19, no. 2, pp. 106–121, 2006.
[39] G. K. Menon and P. M. Elias, “Morphologic basis for a pore-
pathway in mammalian stratum corneum,” Skin Pharmacology,
vol. 10, no. 5-6, pp. 235–246, 1997.
[40] S. Paliwal, G. K. Menon, and S. Mitragotri, “Low-frequency
sonophoresis: ultrastructural basis for stratum corneumperme-
ability assessed using quantumdots,”The Journal of Investigative
Dermatology, vol. 126, no. 5, pp. 1095–1101, 2006.
[41] C. Jacobs, O. Kayser, and R. H. Mu¨ller, “Nanosuspensions as a
new approach for the formulation for the poorly soluble drug
tarazepide,” International Journal of Pharmaceutics, vol. 196, no.
2, pp. 161–164, 2000.
[42] S.Honary andF. Zahir, “Effect of zeta potential on the properties
of nano-drug delivery systems—a review (part 2),” Tropical
Journal of Pharmaceutical Research, vol. 12, no. 2, pp. 255–264,
2013.
[43] R. Cortesi, E. Esposito, S. Gambarin, P. Telloli, E. Menegatti,
and C. Nastruzzi, “Preparation of liposomes by reverse-phase
evaporation using alternative organic solvents,” Journal of
Microencapsulation, vol. 16, no. 2, pp. 251–256, 1999.
[44] A. H. Øien and H. Wiig, “Electrostatic, elastic and hydration-
dependent interactions in dermis influencing volume exclusion
and macromolecular transport,” Journal of Theoretical Biology,
vol. 400, pp. 80–91, 2016.
[45] P. Desai, R. R. Patlolla, and M. Singh, “Interaction of nanopar-
ticles and cell-penetrating peptides with skin for transdermal
drug delivery,” Molecular Membrane Biology, vol. 27, no. 7, pp.
247–259, 2010.
[46] S. Jung, N. Otberg, G. Thiede et al., “Innovative liposomes as
a transfollicular drug delivery system: penetration into porcine
hair follicles,” Journal of Investigative Dermatology, vol. 126, no.
8, pp. 1728–1732, 2006.
[47] S. Shanmugam,C.-K. Song, S.Nagayya-Sriraman et al., “Physic-
ochemical characterization and skin permeation of liposome
formulations containing clindamycin phosphate,” Archives of
Pharmacal Research, vol. 32, no. 7, pp. 1067–1075, 2009.
[48] Y.-K. Song and C.-K. Kim, “Topical delivery of low-molecular-
weight heparin with surface-charged flexible liposomes,” Bio-
materials, vol. 27, no. 2, pp. 271–280, 2006.
[49] M. Kirjavainen, A. Urtti, R. Valjakka-Koskela, J. Kiesvaara,
and J. Mo¨nkko¨nen, “Liposome-skin interactions and their
effects on the skin permeation of drugs,” European Journal of
Pharmaceutical Sciences, vol. 7, no. 4, pp. 279–286, 1999.
